Table 2.

Multivariable outcome analyses of older patients with de novo acute myeloid leukemia

Variables in final model	Complete remission		Disease-free survival		Overall survival
	OR (95% CI)	P-valuea	HR (95% CI)	P-valuea	HR (95% CI)	P-valuea
	NPM1, mutated vs wild-type	3.46 (2.01–5.97)	<0.001	0.60 (0.45–0.81)	<0.001	0.55 (0.44–0.69)	<0.001
U2AF1, mutated vs wild-type	0.40 (0.18–0.90)	0.03
WT1, mutated vs wild-type	0.22 (0.07–0.71)	0.01
Normal karyotype, present vs absent mutated v wild-type	1.70 (1.06–2.74)	0.03
SF1, mutated vs wild-type
FLT3-ITD, present vs absent			2.30 (1.62–3.26)	<0.001	1.85 (1.43–2.39)	<0.001
WBC, per 50-unit increase			1.22 (1.06–1.41)	0.007
Complex karyotype,b present vs absent			4.21 (2.45–7.21)	<0.001	1.78 (1.24–2.55)	0.002
BCOR, mutated vs wild-type					1.82 (1.23–2.69)	0.003
TP53, mutated vs wild-type					1.91 (1.25–2.93)	0.003
t(9;11), present vs absent					2.19 (1.07–4.47)	0.03

Abbreviations: CI, confidence interval; FLT3-ITD, internal tandem duplication of the FLT3 gene; HR, hazard ratio; OR, odds ratio; WBC, white blood cell count.

An OR <1 (>1) means lower (higher) CR rate for first category listed of a dichotomous variable or higher values of a continuous variable. A HR >1 (<1) corresponds to a higher (lower) risk for first category listed of a dichotomous variable or higher values of a continuous variable. A limited backward selection technique was used to build the final model for achievement of complete remission, disease-free and overall survival. Variables considered in the model were variables that were significant at the likelihood ratio test P-value <.20 from the univariable models (detailed in the Supplementary Information).

^aP-values for CR were determined by logistic regression. P-values for DFS and OS were determined using Cox proportional hazards regression.

^bComplex karyotype is defined by the presence of ≥3 chromosome aberrations.